| CANTARGIA AB |
| Schweden |
| Gesundheit |
| SE0006371126 / A2JAZX |
| 7V3 (Frankfurt) |
| FRA:7V3, ETR:7V3, 7V3:GR |
| - |
| https://cantargia.com/ |
|
Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface recepto..
>Volltext.. |
| 90.43 Mio. EUR |
| 64.77 Mio. EUR |
| 29.35 Mio. EUR |
| 14.61 Mio. EUR |
| 13.62 Mio. EUR |
| 0.05 EUR |
| - |
| 26.11 Mio. EUR |
| 13.91 Mio. EUR |
| 9.41 |
| - |
| - |
| - |
| - |
| - |
| - |
| CANTARGIA |
| 08.04.26 |
|